In this clinical context, the pharmacological blockade of TLR4 or the NLRP3/IL-1β/IL-1 receptor axis may provide a therapeutic strategy for preventing and/or treating the vascular alterations associated to metabolic diseases. This evidence concerns the gene TLR4 and metabolic disease.